WO2006013012A3 - Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) - Google Patents
Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) Download PDFInfo
- Publication number
- WO2006013012A3 WO2006013012A3 PCT/EP2005/007949 EP2005007949W WO2006013012A3 WO 2006013012 A3 WO2006013012 A3 WO 2006013012A3 EP 2005007949 W EP2005007949 W EP 2005007949W WO 2006013012 A3 WO2006013012 A3 WO 2006013012A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- diseases
- nap1
- napsin
- therapeutics
- diagnostics
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title abstract 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 7
- 101100186433 Dictyostelium discoideum napA gene Proteins 0.000 title 1
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 title 1
- 102100027343 Napsin-A Human genes 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 208000012902 Nervous system disease Diseases 0.000 abstract 2
- 208000025966 Neurological disease Diseases 0.000 abstract 2
- 208000012931 Urologic disease Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000002124 endocrine Effects 0.000 abstract 2
- 208000014951 hematologic disease Diseases 0.000 abstract 2
- 208000015181 infectious disease Diseases 0.000 abstract 2
- 230000004054 inflammatory process Effects 0.000 abstract 2
- 208000030159 metabolic disease Diseases 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 208000023504 respiratory system disease Diseases 0.000 abstract 2
- 208000014001 urinary system disease Diseases 0.000 abstract 2
- 102100021324 5-azacytidine-induced protein 2 Human genes 0.000 abstract 1
- 101000895045 Homo sapiens 5-azacytidine-induced protein 2 Proteins 0.000 abstract 1
- 101000680450 Homo sapiens tRNA (adenine(37)-N6)-methyltransferase Proteins 0.000 abstract 1
- 108090001007 Interleukin-8 Proteins 0.000 abstract 1
- 238000003556 assay Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000046389 human TRMO Human genes 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
- G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
- G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
- G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
- G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
- G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
- G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
- G01N2333/96472—Aspartic endopeptidases (3.4.23)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Endocrinology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention provides a human NAP1 which is associated with the cardiovascular diseases, infections, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases and inflammation. The invention also provides assays for the identification of compounds useful in the treatment or prevention of cardiovascular diseases, infections, endocrinological diseases, metabolic diseases, cancer, gastroenterological diseases, hematological diseases, muscle skeleton diseases, neurological diseases, urological diseases, respiratory diseases and inflammation. The invention also features compounds which bind to and/or activate or inhibit the activity of NAP1 as well as pharmaceutical compositions comprising such compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04018443.4 | 2004-08-04 | ||
| EP04018443 | 2004-08-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2006013012A2 WO2006013012A2 (en) | 2006-02-09 |
| WO2006013012A3 true WO2006013012A3 (en) | 2006-04-06 |
Family
ID=35427455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/EP2005/007949 WO2006013012A2 (en) | 2004-08-04 | 2005-07-21 | Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2006013012A2 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102007062411A1 (en) | 2007-12-20 | 2009-06-25 | Justus-Liebig-Universität Giessen | Medicines for the treatment of fibrosing lung diseases |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036550A2 (en) * | 1998-01-16 | 1999-07-22 | Incyte Pharmaceuticals, Inc. | Human protease molecules |
| WO1999060160A1 (en) * | 1998-05-21 | 1999-11-25 | Diadexus Llc | A novel method of diagnosing, monitoring, and staging lung cancer |
| JP2001172200A (en) * | 1999-12-17 | 2001-06-26 | Meneki Seibutsu Kenkyusho:Kk | Antibody against human napsin-a and medicament using the same antibody |
-
2005
- 2005-07-21 WO PCT/EP2005/007949 patent/WO2006013012A2/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1999036550A2 (en) * | 1998-01-16 | 1999-07-22 | Incyte Pharmaceuticals, Inc. | Human protease molecules |
| WO1999060160A1 (en) * | 1998-05-21 | 1999-11-25 | Diadexus Llc | A novel method of diagnosing, monitoring, and staging lung cancer |
| JP2001172200A (en) * | 1999-12-17 | 2001-06-26 | Meneki Seibutsu Kenkyusho:Kk | Antibody against human napsin-a and medicament using the same antibody |
Non-Patent Citations (3)
| Title |
|---|
| CRONSHAW REBECCA F ET AL: "Inhibition of human napsin A.", PROTEIN AND PEPTIDE LETTERS, vol. 10, no. 1, February 2003 (2003-02-01), pages 35 - 42, XP009058607, ISSN: 0929-8665 * |
| PATENT ABSTRACTS OF JAPAN vol. 2000, no. 23 10 February 2001 (2001-02-10) * |
| UENO T ET AL: "Aspartic proteinase napsin is a useful marker for diagnosis of primary lung adenocarcinoma.", BRITISH JOURNAL OF CANCER, vol. 88, no. 8, 22 April 2003 (2003-04-22), pages 1229 - 1233, XP002359371, ISSN: 0007-0920 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006013012A2 (en) | 2006-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2006027147A3 (en) | Diagnostics and therapeutics for diseases associated with adrenomedullin receptor (amdr) | |
| WO2005093092A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 44 (gpr44) | |
| WO2005106012A3 (en) | Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1) | |
| WO2006010498A3 (en) | Diagnostics and therapeutics for diseases associated with methionine aminopeptidase 2 (metap2) | |
| WO2006010517A3 (en) | Diagnostics and therapeutics for diseases associated with fibroblast activation protein (fap) | |
| WO2005100990A3 (en) | Diagnostics and therapeutics for diseases associated with purinoceptor 2 type y (p2y2) | |
| WO2005106491A3 (en) | Diagnostics and therapeutics for diseases associated with serum/glucocorticoid regulated kinase 1 (sgk1) | |
| WO2006010514A3 (en) | Diagnostics and therapeutics for diseases associated with dual specificity mitogen-activated protein kinase kinase 5 (map2k5) | |
| WO2006013012A3 (en) | Diagnostics and therapeutics for diseases associated with napsin 1 (nap1) | |
| WO2005113786A3 (en) | Diagnostics and therapeutics for diseases associated with chymase (cma1) | |
| WO2005106486A3 (en) | Diagnostic and therapeutics for diseases associated with dipeptidyl-peptidase 3(dpp3) | |
| WO2006021343A3 (en) | Diagnostics and therapeutics for diseases associated with 5-hydroxytryptamine receptor 3a (5-ht3a) | |
| WO2005093091A3 (en) | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 26 (gpr26) | |
| WO2006013015A3 (en) | Diagnostics and therapeutics for diseases associated with marapsin (mpn) | |
| WO2005119263A3 (en) | Diagnostics and therapeutics for diseases associated with g protein-coupled receptor 92 (gpr92) | |
| WO2006010497A3 (en) | Diagnostics and therapeutics for diseases associated with choline kinase (chk) | |
| WO2005100997A3 (en) | Diagnostics and therapeutics for diseases associated with tachykinin receptor 3 (tacr3) | |
| WO2005114210A8 (en) | Diagnostics and therapeutics for diseases associated with g protein-dependent receptor kinase 3 (grk3) | |
| WO2006013014A3 (en) | Diagnostics and therapeutics for diseases associated with prostate-specific membrane antigen-like protein (psmal) | |
| WO2005026719A3 (en) | Diagnostics and therapeutics for diseases associated with transporter slc22a3 (slc22a3) | |
| WO2005101009A3 (en) | Diagnostics and therapeutics for diseases associated with tachykinin receptor 2 (tacr2) | |
| WO2005101004A8 (en) | Diagnostics and therapeutics for diseases associated with purinoceptor 1 type y (p2y1) | |
| WO2006010495A3 (en) | Diagnostics and therapeutics for diseases associated with carboxypeptidase a3 (cpa3) | |
| WO2006005470A3 (en) | Diagnostics and therapeutics for diseases associated with mas related g-protein coupled receptor e (mrge) | |
| WO2006013013A3 (en) | Diagnostics and therapeutics for diseases associated with protective protein for beta-galactosidase (ppgb) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |